Vancomycin Placebo

DRUG5 trials

Conditions

Allogeneic Hematopoietic Stem Cell TransplantationClostridium DifficileClostridium Difficile ColonizationClostridium Difficile DiarrheaColitis, UlcerativeHepatocellular carcinomaUlcerative Colitis

Early Phase 1

Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients

WithdrawnNCT04246151

Hamilton Health Sciences CorporationClostridium Difficile Colonization, Clostridium Difficile Diarrhea

Start: 2022-09-01End: 2024-09-12Updated: 2025-02-20

Phase 1

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

CompletedNCT04995653

Seres Therapeutics, Inc.Allogeneic Hematopoietic Stem Cell Transplantation

Start: 2021-11-24End: 2024-07-23Updated: 2024-10-01

Phase 2

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

TerminatedNCT05370885

Vedanta Biosciences, Inc.Colitis, Ulcerative, Ulcerative Colitis

Start: 2023-05-08End: 2025-08-29Updated: 2025-12-17

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blind Phase II trial (FLORA)

RecruitingCTIS2023-506887-15-00

Universitaetsklinikum Heidelberg AöRHepatocellular carcinoma

Start: 2025-07-14Target: 48Updated: 2026-01-22

Phase 3

Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea

WithdrawnNCT02801656

Memorial University of NewfoundlandClostridium Difficile

Start: 2020-12-01End: 2022-09-01Updated: 2022-04-29

BMJ Open2025-09-012 citations

Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT.

Journal of Clinical Oncology2025-05-28

Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).

Journal of Clinical Oncology2024-06-01

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Blood2023-11-02

A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.

Journal of Clinical Oncology2023-06-011 citations

A phase 1b study to evaluate safety, tolerability, pharmacokinetics, and efficacy of SER-155 in adults undergoing hematopoietic stem cell transplantation to reduce the risk of infection and graft versus host disease (NCT04995653).

Journal of Clinical Oncology2022-06-012 citations